Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo | |
| 11/11/2024 | Mkt Outperform → Mkt Perform | JMP Securities | ||
| 11/8/2024 | Outperform → Mkt Perform | William Blair | ||
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities | |
| 10/30/2024 | $7.00 → $2.50 | Neutral → Sell | Citigroup | |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | ||
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays | |
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein |
Wells Fargo upgraded CVS Health from Equal Weight to Overweight and set a new price target of $66.00 from $60.00 previously
JMP Securities downgraded Agilon Health from Mkt Outperform to Mkt Perform
William Blair downgraded Agilon Health from Outperform to Mkt Perform
3 - CVS HEALTH Corp (0000064803) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
3 - HUMANA INC (0000049071) (Issuer)
CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, R.I., Nov. 18, 2024 /PRNewswire/ -- The Board of Directors of CVS Health (NYSE:CVS) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. "In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today. As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pha
WOONSOCKET, R.I., Nov. 19, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Dr. Sreekanth Chaguturu will be President, Health Care Delivery, in addition to his current role as Executive Vice President and Chief Medical Officer of CVS Health. Dr. Chaguturu replaces Mike Pykosz, who has decided to leave the company. "Sree and I worked closely together when he started at CVS Health, serving as chief medical officer of CVS Caremark. In that role, and as the leader of Medical Affairs at our company, Sree has served as a trusted advisor to our clients, their members
CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, R.I., Nov. 18, 2024 /PRNewswire/ -- The Board of Directors of CVS Health (NYSE:CVS) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. "In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our
Revere Medical Enters into Agreement to Acquire CareMax's Management Services Organization Agreement in Principle Reached with "Stalking Horse" for Core Centers' Assets Sale Transactions to be Implemented Through an Expedited Prearranged Chapter 11 Plan Supported by 100% of CareMax's Secured Lenders CareMax Secures $30.5 Million in Debtor in Possession Financing to Support Operations and Continuing Provision of Healthcare Services Throughout Restructuring Process CareMax, Inc. (NASDAQ:CMAX, CMAXW)) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced it has entered into an agreement to sell its management services organization
4 - agilon health, inc. (0001831097) (Issuer)
4 - American Oncology Network, Inc. (0001839998) (Issuer)
4 - American Oncology Network, Inc. (0001839998) (Issuer)
Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c
Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior yearThird quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segmentGenerated year-to-date cash flow from operations of $7.2 billionCEO Commentary "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Serv
Reports 3Q24 earnings per share (EPS) of $3.98 on a GAAP basis, Adjusted EPS of $4.16; reports YTD 2024 EPS of $15.72 on a GAAP basis, $18.35 on an Adjusted basis Updates FY 2024 EPS guidance to 'at least $12.89' on a GAAP basis, 'at least $16.00' on an Adjusted basis; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent Raises 2024 individual Medicare Advantage annual membership growth by 40,000 to now anticipate annual growth of approximately 265,000, or approximately 5 percent Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9:00 a.m. ET question and answer session to discuss its financial results for
F-3/A - Akso Health Group (0001702318) (Filer)
DEFA14A - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - agilon health, inc. (0001831097) (Subject)
SC 13G/A - agilon health, inc. (0001831097) (Subject)
Builds On Ongoing Collaboration With Google Health To Develop Population Health Solutions And Address Healthcare Challenges
TD Cowen analyst Gary Taylor maintains Humana (NYSE:HUM) with a Buy and raises the price target from $396 to $407.